Effectiveness of finerenone for proteinuria reduction in IgA nephropathy: A multicenter target trial emulation

Background Finerenone, a non-steroidal mineralocorticoid receptor antagonist, reduces proteinuria in diabetic kidney disease. Real-world evidence in IgA nephropathy (IgAN) remains limited to single-center studies that are often mixed with immunosuppression and susceptible to immortal time bias. Methods We emulated a target trial using data from a multicenter retrospective registry across 25 hospitals in China (2022–2026). Eligible adults had biopsy-proven IgAN, persistent proteinuria > 0.5 g/day despite stable renin-angiotensin system (RAS) inhibitor therapy, and eGFR ≥15 mL/min/1.73 m². Using the clone-censor-weight (CCW) approach with a 3-month grace period, we compared finerenone initiation with non-initiation. The primary outcome was a composite of ≥ 40% reduction in proteinuria from baseline with stable kidney function. We additionally performed marginal structural model (MSM) analyses, including an exploratory dose analysis, eGFR trajectory analysis, and prespecified subgroup analyses. Results Among 238 patients, 141 received finerenone, most at an initial dose of 10 mg daily. Of these, 119 started treatment within the 3-month grace period. This initiation strategy was associated with a higher probability of the primary composite outcome (hazard ratio [HR], 1.51; 95% CI, 1.17 to 1.96; absolute risk difference at 12 months, 22.3%; 95% CI, 5.9% to 38.7%). The association was directionally consistent in MSM analyses (HR, 1.83; 95% CI, 1.29 to 2.59). Monthly eGFR slopes did not differ between strategies (−0.05 mL/min/1.73 m² per month; P = 0.82). Hyperkalemia occurred in 4 patients, including one in the finerenone initiation strategy. Conclusion In this multicenter target-trial emulation, finerenone initiation as an adjunct to background RAS inhibitors was associated with clinically meaningful proteinuria reduction in patients with IgAN under current supportive care. These data may help inform real-world use, including up-titration to 20 mg when serum potassium and kidney function permit.

Authors

Institutions

Publication Details

Journal
Clinical Kidney Journal
Published
2026-11-19
DOI
https://doi.org/10.1093/ckj/sfag401
Primary Topic
Renal Diseases and Glomerulopathies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Effectiveness of finerenone for proteinuria reduction in IgA nephropathy: A multicenter target trial emulation

Xiangcheng Xie, Santao Ou, Wei Qin, Chen Tang et al.
Clinical Kidney Journal
Renal Diseases and Glomerulopathies
article

Effectiveness of finerenone for proteinuria reduction in IgA nephropathy: A multicenter target trial emulation

Xiangcheng Xie, Santao Ou, Wei Qin, Chen Tang, Ji-Cheng Lv, Jing Li, Hong Zhang, Wanhong Lu, Xinrong Zou, Lifen Wang, Yanqing Chi, Ya-Feng Li, Yu Yan, Gui-Sen Li
article en

Abstract

Background Finerenone, a non-steroidal mineralocorticoid receptor antagonist, reduces proteinuria in diabetic kidney disease. Real-world evidence in IgA nephropathy (IgAN) remains limited to single-center studies that are often mixed with immunosuppression and susceptible to immortal time bias. Methods We emulated a target trial using data from a multicenter retrospective registry across 25 hospitals in China (2022–2026). Eligible adults had biopsy-proven IgAN, persistent proteinuria > 0.5 g/day despite stable renin-angiotensin system (RAS) inhibitor therapy, and eGFR ≥15 mL/min/1.73 m². Using the clone-censor-weight (CCW) approach with a 3-month grace period, we compared finerenone initiation with non-initiation. The primary outcome was a composite of ≥ 40% reduction in proteinuria from baseline with stable kidney function. We additionally performed marginal structural model (MSM) analyses, including an exploratory dose analysis, eGFR trajectory analysis, and prespecified subgroup analyses. Results Among 238 patients, 141 received finerenone, most at an initial dose of 10 mg daily. Of these, 119 started treatment within the 3-month grace period. This initiation strategy was associated with a higher probability of the primary composite outcome (hazard ratio [HR], 1.51; 95% CI, 1.17 to 1.96; absolute risk difference at 12 months, 22.3%; 95% CI, 5.9% to 38.7%). The association was directionally consistent in MSM analyses (HR, 1.83; 95% CI, 1.29 to 2.59). Monthly eGFR slopes did not differ between strategies (−0.05 mL/min/1.73 m² per month; P = 0.82). Hyperkalemia occurred in 4 patients, including one in the finerenone initiation strategy. Conclusion In this multicenter target-trial emulation, finerenone initiation as an adjunct to background RAS inhibitors was associated with clinically meaningful proteinuria reduction in patients with IgAN under current supportive care. These data may help inform real-world use, including up-titration to 20 mg when serum potassium and kidney function permit.

Clinical Kidney Journal
Hebei Medical University (CN), Xinjiang Medical University (CN), Sun Yat-sen University (CN), Hubei University of Chinese Medicine (CN), Sichuan University (CN), Sir Run Run Shaw Hospital (CN), First Affiliated Hospital of Xinjiang Medical University (CN), Affiliated Hospital of Southwest Medical University (CN), Third Hospital of Hebei Medical University (CN), West China Hospital of Sichuan University (CN), Hubei Provincial Hospital of Traditional Chinese Medicine (CN), Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital (CN), First Affiliated Hospital of Xi'an Jiaotong University (CN), Peking University People's Hospital (CN), Peking University First Hospital (CN), Southern Medical University Shenzhen Hospital (CN), Eighth Affiliated Hospital of Sun Yat-sen University (CN), Southern Medical University (CN), Zhejiang University (CN), Xi'an Jiaotong University (CN)
Renal Diseases and Glomerulopathies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon